Analysts Set Inspire Medical Systems, Inc. (NYSE:INSP) PT at $66.19

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have received an average rating of “Hold” from the nineteen analysts that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, eleven have given a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $66.50.

A number of brokerages have recently commented on INSP. Zacks Research raised Inspire Medical Systems from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 17th. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a report on Tuesday, August 4th. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Finally, UBS Group started coverage on shares of Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target for the company.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $72.70 on Friday. The company has a fifty day moving average of $57.11 and a 200-day moving average of $52.65. The company has a market capitalization of $2.10 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 5.55 and a beta of 0.70. Inspire Medical Systems has a 52-week low of $38.91 and a 52-week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.Inspire Medical Systems’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC raised its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after buying an additional 580 shares during the period. Havemeyer Place LP bought a new stake in Inspire Medical Systems in the 4th quarter worth $39,000. Smartleaf Asset Management LLC increased its position in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Inspire Medical Systems by 379.0% in the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after acquiring an additional 758 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.